Polsinelli PC, Life Sciences | Chambers USA Profile

Regional Rankings
Global
Asia-Pacific
Brazil
Canada
Europe
France
Greater China Region
Latin America
UK
UK Bar
Germany
USA
Specialist Rankings
NewLaw
Crisis & Risk Management
FinTech
High Net Worth
Litigation Support
Spotlight Rankings
USA: Spotlight
Content
Global Practice Guides
Expert Focus
Legal Articles
Customer Voices
Chambers Content
Events
Guide Launch Dates
Upcoming Events
Browse All Events
Event Sponsorship
About Our Events
DEI Events
Amplify your presence
Profile Platform
Amplify your ranking and be more discoverable
Includes:

Online Profile

Referee Management

Research Analytics

Marketing Toolkit

Plaques
Improve your performance
Insight
Improve your ranking with unique market insight
Includes:

Client and Market Intelligence

Client Intelligence

Rankings Data Hub

Business Intelligence
Market PulseNew
Showcase your expertise
Global Practice Guides Contributions
Highlight your subject matter expertise
Expert Focus
Provide commentary on key legal matters
In-depth Overviews
Events Sponsorship
Global Practice Guides
View our latest publications
Elevate your talent strategies
Chambers Talent
Access a range of ways to gain valuable insights to inform talent strategies
Leading Teams
Heighten your understanding of and identify the key drivers of talent retention and motivation
Chambers Student
Chambers Associate
Discover what's new at Chambers and Partners - click here to find out more
Submissions
Submissions Process
Methodology
Research Schedule
Research Team
Help
My Account

Chambers Review

Provided by Chambers

Life Sciences - USA - Nationwide

5

Band 5

What the Team is Known For

Polsinelli PC is a respected national firm with a strong track record acting on behalf of major life sciences companies. The team's capabilities include complex high stakes IP litigation, as well as M&A and other transactional mandates.

Notable practitioners

Chad Landmon is a key contact.

View ranking table

Work Highlights

Polsinelli PC continued to represent MSN Pharmaceuticals in federal court challenges related to MSN’s FDA approval to launch the first US generic version of Novartis’s blockbuster heart‑failure drug, ENTRESTO.